P-BCMA-ALLO1 is licensed to Roche for the treatment of relapsed/refractory multiple myeloma. Credit: SkazovD/Shutterstock. Poseida Therapeutics has received the Regenerative Medicine Advanced Therapy (RMAT) designation
Kamau’s lead investigational programme, nula-cel, which is based on HDR editing, is currently in clinical development for sickle cell disease. Credit: Babul Hosen /Shutterstock. MaxCyte,
30,000 new cases of multiple myeloma are diagnosed each year in China. Credit: luchschenF/Shutterstock. China’s National Medical Products Administration’s (NMPA) Center for Drug Evaluation (CDE)
Ocrevus Zunovo’s most common adverse events were injection reactions, which were either mild or moderate in nature. Credit: pedro7merino/Shutterstock. Roche has secured approval from the
FS001 incorporates a stable and cleavable linker with a potent topoisomerase I inhibitor. Credit: 15Studio/Shutterstock. Ipsen has entered an exclusive global licensing agreement with Foreseen
Parkinson’s Disease is a progressive neurodegenerative disorder. Credit: Momentum studio/Shutterstock. Bayer and Asklepios BioPharmaceutical (AskBio) have announced US Food and Drug Administration (FDA) fast track
The funding will help further the development of its pipeline projects targeting colorectal and ovarian cancers. Credit: NTshutterth/Shutterstock. Pan Cancer T, a US biotech firm
The partnership builds on Tiba’s existing efforts to tackle influenza pandemic threats. Credit: fizkes/Shutterstock. Tiba Biotech, a US preclinical biopharmaceutical company based in Cambridge, Massachusetts,